Journal
BIOCHEMICAL PHARMACOLOGY
Volume 210, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2023.115489
Keywords
Hepatocellular carcinoma; Lenvatinib; DNMT1; UHRF1; ERK; MAPK
Categories
Ask authors/readers for more resources
In this study, it was found that Lenvatinib can inhibit the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma cells. This effect is achieved by negatively regulating the transcription of UHRF1 and DNMT1 through the ERK/MAPK pathway, as well as promoting their protein degradation through the ubiquitin-proteasome pathway. Consequently, the expression of E-Cadherin is upregulated and the adhesion and metastasis of Huh7 cells are attenuated in vivo.
Hepatocellular carcinoma (HCC) is one of the most common causes of malignancy-related deaths. Lenvatinib, as a multi-targeted tyrosine kinase inhibitor, has gained increasing attention for its antitumor activity. However, the effect and mechanisms of Lenvatinib on HCC metastasis are virtually unknown. In this study, we revealed that Lenvatinib inhibited HCC cell motility and epithelial mesenchymal transition (EMT), along with cell adhesion and extension. Concomitant high DNMT1 and UHRF1 mRNA levels were in HCC patients and indicated worse prognosis. On the one hand, Lenvatinib modulated the transcription of UHRF1 and DNMT1via negatively regulation of ERK/MAPK pathway. On the other hand, Lenvatinib downregulated DNMT1 and UHRF1 expression by promoting their protein degradation through ubiquitin-proteasome pathway, consequently, resulting in upregulation of E-Cadherin. Moreover, Lenvatinib attenuated Huh7 cell adhesion and metastasis in vivo. Our findings provided insight into the intriguing molecular mechanisms regarding the anti-metastasis effect of Lenvatinib in HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available